Speed – and staying close to the customer – is the key to commercialising new materials for electronics. But you can’t do this in Europe, says Thomas Geelhaar, head of R&D at Merck Chemicals.
The UK biotech sector has fallen victim to the mayhem in the capital markets. After a year of falling share prices, five quoted companies have put up “for sale” signs.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.